Round up to 11 vials
Its using carefully calibrated amounts of medications like semaglutide and tirzepatide (the active pharmaceutical ingredient found in Ozempic, Wegovy, Mounjaro, and Zepbound) that may support metabolic function, reduce inflammation, and promote cardiovascular health without substantial weight change
General principles for peptide-based injectables (such as refrigeration and protection from light) may apply, but the specific requirements for your trial supply take precedence
These circulating markers are linked to inflammation and endothelial dysfunction, which can lead to cardiovascular events
A small trial including 8 patients with T1D showed improved postprandial hyperglycemia despite 20% insulin dose reduction ( 5 Cardiovascular and renal outcomes with GLP-1RA in T1D In patients with T2D, large RCT studies have shown that GLP-1RA treatment reduces the risk of cardiovascular and renal outcomes ( 6 Practical issues when prescribing GLP-1RA in T1D GLP-1RA are not currently approved for treatment of T1D, but they may still be covered by insurance if prescribed to treat obesity in these patients (although insurance coverage for obesity remains limited)
But keeping it off after you stop taking the drug can be a big challenge
